Celsis Initiates Patent Infringement Action Against XenoTech and Sekisui

BALTIMORE, February 2 - Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed a
patent infringement lawsuit against XenoTech LLC, Sekisui Chemical Co. Ltd.,
and Sekisui Medical Co. Ltd. in the United States District Court for the
Northern District of Illinois in Chicago. XenoTech and Sekisui Medical are
wholly-owned subsidiaries of Sekisui Chemical. The complaint alleges that
certain processes and methods performed by XenoTech associated with its in
vitro drug testing services and its pooled cryopreserved hepatocyte products,
including CryoXTreme(TM), infringes one or more claims of U.S. Patent No.
7,604,929 (the '929 patent). The complaint also alleges that Sekisui Chemical
and Sekisui Medical are inducing infringement of the '929 patent and seeks
monetary damages and injunctive relief. Celsis IVT is represented by Jordan
Sigale and Adam Kelly of Loeb & Loeb LLP.

The '929 patent relates to processes and methods for producing
cryopreserved hepatocytes. In general, this technology combines hepatocytes
from multiple donors to create large lots with targeted activity levels, the
result of which is a product that speeds up decision making and reduces the
time and cost of drug research. Since 2005, Celsis IVT has used this novel
technology to create its unique LiverPool(TM) products for drug discovery
research. Major pharmaceutical companies around the world have incorporated
these LiverPool products into their standard research protocols. Research
conducted with LiverPool has confirmed its outstanding efficacy as a research
tool in numerous ADME-Tox assays, including metabolic stability and clearance
studies. Additional LiverPool product information is available online at
www.celsis.com/liverpool.

"Innovation is the lifeblood of Celsis and the entire life sciences
industry. It must be protected if we are to advance the cause of
cost-effective drug discovery," said Jay LeCoque, CEO of Celsis. "We are
disappointed that we are forced to take a litigation path after an
unsuccessful attempt to meaningfully discuss our proprietary rights with
XenoTech," he added, "Yet, we remain hopeful that the Defendants will
cooperate with us to reach a successful resolution."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis International Ltd., is the premier
world provider of specialized in vitro products for the study of metabolism,
drug-drug interactions and toxicity in drug discovery and development. Since
1990, pharmaceutical and biotechnology companies have relied on
Baltimore-based Celsis IVT for quality in vitro products for lead
optimization. Celsis IVT products deliver faster time to results, enabling
more productive and cost-effective research. Celsis IVT's patented LiverPool
products, cryo-plateable hepatocytes (the world's largest inventory) and
other ADMET research tools are available worldwide. Visit www.celsis.com/ivt
for more information.

About Celsis International Ltd.

Chicago-based Celsis International Ltd. is a leading global provider of
innovative life science products and laboratory services to the
pharmaceutical and consumer products industries. Each Celsis division
delivers substantial time and cost savings to its customers while ensuring
product quality and safety for consumers. Celsis' extensive client base
includes leading pharmaceutical and consumer products companies, including
all 25 of the top 25 pharmaceutical companies worldwide. Visit
www.celsis.com.

Cindy Lieberman - Corporate Marketing of Celsis International, +1-312-476-1200, clieberman at celsis.com; or Andrea Davis of Outlook Marketing Services, Inc., +1-312-873-3421, andrea at outlookmarketingsrv.com, for Celsis International Ltd.